VBI Vaccines (VBIV) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
VBI Vaccines Inc. has entered restructuring proceedings under the CCAA to explore strategic alternatives after a financial review. The company secured initial court protection and intends to facilitate a sale through a court-approved process while seeking support from U.S. and Israeli courts for its subsidiaries. VBI’s common shares are expected to stop trading on Nasdaq as the company transitions away from public reporting.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.
